Article in The Journal of organic chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors.
William D LambertDepartment of Chemistry and Biochemistry, University of Delaware, Newark, Delaware 19716, United States.
Stephanie TsangDepartment of Chemistry and Biochemistry, University of Delaware, Newark, Delaware 19716, United States.
Ashlyn S HillmanDepartment of Chemistry and Biochemistry, University of Delaware, Newark, Delaware 19716, United States.
Chuanqi WangDepartment of Chemistry and Biochemistry, University of Delaware, Newark, Delaware 19716, United States.
Christopher W Am EndePfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States.ORCID 0000-0001-8832-9641
Joseph M FoxDepartment of Chemistry and Biochemistry, University of Delaware, Newark, Delaware 19716, United States.ORCID 0000-0002-8258-1640
Funding
Predictive Modeling & Optimal Control Framework for Model-Based Epidemic Response in DelawareP20GM103446 · NIGMS · UNIVERSITY OF DELAWARE · PI Shawn W Polson · 2012 to 2026
$67.2M
This renovation project will create over 1455 sq. ft. of state- of-the-art reseaP20GM104316 · NIGMS · UNIVERSITY OF DELAWARE · PI FOX, JOSEPH M · 2014 to 2024
$26.8M
Toolkit for Fast, Multipurpose and Inducible Bioorthogonal ChemistryR01GM132460 · NIGMS · UNIVERSITY OF DELAWARE · PI JOSEPH M FOX · 2019 to 2026
$4.2M
Discovery of Chemical Probes and Therapeutic Leads: Thermo Exploris 240P30GM159572 · NIGMS · UNIVERSITY OF DELAWARE · PI JOSEPH M FOX · 2025 to 2026
$3.8M
Chemistry-Biology Interface Predoctoral Training Grant 2024-2029T32GM133395 · NIGMS · UNIVERSITY OF DELAWARE · PI Catherine Leimkuhler Grimes · 2019 to 2026
$3.7M
Development of an Efficient 18F labeling technology based on tetrazine trans-cyclooctene ligationR01CA287184 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOSEPH M FOX, Zibo Li · 2024 to 2026
$1.9M
High Sensitivity NMR Spectrometer with CryoprobeS10OD025185 · OD · UNIVERSITY OF DELAWARE · PI FOX, JOSEPH M · 2019 to 2019
$930k
Q-Exactive Orbitrap LC-MC/MS SystemS10OD016267 · OD · UNIVERSITY OF DELAWARE · PI JOHNSTON, MURRAY V · 2013 to 2013
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Second-Generation Catalyst System for Ag-Mediated Liebeskind-Srogl Coupling of Tetrazine Thioethers with Arylboronic Acids. · full record | OpenQuestion